Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 7 December 2011 and on 8 December 2011
| Source: Novo Nordisk A/S
For release content, please refer to the attachment.
Recommended Reading
-
FDA has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term
Read More -
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Read More